Business
Target engagement/chemoproteomics contract
Proteome Sciences plc has announced a significant new clinical contract related to its target engagement/chemoproteomics platform, which is anticipated to precede a new clinical trial program commencing later in 2026. The company highlighted continued momentum and growth in its chemoproteomics services, with the Executive Chairman expressing delight at the new contract and the considerable interest generated at the recent American Society for Mass Spectrometry meeting. Disclaimer*
About this update from Proteome Sciences Plc
22 June 2026 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation Proteome Sciences plc ("Proteome Sciences" or the "Company") Target engagement/chemoproteomics contract Proteome Sciences plc (AIM:PRM) is pleased to announce that the Company has secured a further significant clinical contract connected to its target engagement/chemoproteomics platform. The Company anticipates this contract being a precursor to a new clinical trial programme that will be initiated later in 2026. Christopher Pearce, Executive Chairman, commented: "We are delighted that the momentum and growth from our chemoproteomics services is continuing in the current year, as highlighted by this new contract. The Company also generated considerable interest and attention at the recent American Society for Mass Spectrometry (ASMS) meeting in San Diego, USA earlier in June and we look forward to providing shareholders with further updates regarding our chemoproteomics workstreams in due course". Proteome Sciences plc Christopher Pearce, Executive Chairman Tel: +44 (0) 20 7043 2116 Richard Dennis, Chief Commercial Officer SP Angel Corporate Finance LLP (Nominated Adviser & Broker) David Hignell/Matthew Johnson/Josh Ray (Corporate Finance) Vadim Alexandre (Corporate Broking) Tel: +44 (0) 20 3470 0470 About Proteome Sciences plc. (www.proteomics.com) Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift reveals the sel...
View stock analysis, news, and events for Proteome Sciences Plc